|
1
|
Lawoyin JO, Lawoyin DO and Aderinokun G:
Intra-oral squamous cell carcinoma in Ibadan: A review of 90 cases.
Afr J Med Med Sci. 26:187–188. 1997.PubMed/NCBI
|
|
2
|
Exarchos KP, Goletsis Y and Fotiadis DI: A
multiscale and multiparametric approach for modeling the
progression of oral cancer. BMC Med Inform Decis Mak. 12:1362012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rautava J, Luukkaa M, Heikinheimo K, Alin
J, Grenman R and Happonen RP: Squamous cell carcinomas arising from
different types of oral epithelia differ in their tumor and patient
characteristics and survival. Oral Oncol. 43:911–919. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Funk GF, Karnell LH, Robinson RA, Zhen WK,
Trask DK and Hoffman HT: Presentation, treatment, and outcome of
oral cavity cancer: A National Cancer Data Base report. Head Neck.
24:165–180. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mehrotra R, Singh MK, Pandya S and Singh
M: The use of an oral brush biopsy without computer-assisted
analysis in the evaluation of oral lesions: A study of 94 patients.
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 106:246–253.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tanaka T, Tanaka M and Tanaka T: Oral
carcinogenesis and oral cancer chemoprevention: A review. Pathol
Res Int. 2011:4312462011. View Article : Google Scholar
|
|
8
|
Inagi K, Takahashi H, Okamoto M, Nakayama
M, Makoshi T and Nagai H: Treatment effects in patients with
squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl.
25–29. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shingaki S, Takada M, Sasai K, Bibi R,
Kobayashi T, Nomura T and Saito C: Impact of lymph node metastasis
on the pattern of failure and survival in oral carcinomas. Am J
Surg. 185:278–284. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamoshida S, Shiogama K, Shimomura R,
Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K and Tsutsumi Y:
Immunohistochemical demonstration of fluoropyrimidine-metabolizing
enzymes in various types of cancer. Oncol Rep. 14:1223–1230.
2005.PubMed/NCBI
|
|
11
|
Miyoshi Y, Uemura H, Ishiguro H, Kitamura
H, Nomura N, Danenberg PV and Kubota Y: Expression of thymidylate
synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase,
and orotate phosphoribosyl transferase in prostate cancer. Prostate
Cancer Prostatic Dis. 8:260–265. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bissery MC, Guénard D, Guéritte-Voegelein
F and Lavelle F: Experimental antitumor activity of taxotere (RP
56976, NSC 628503), a taxol analogue. Cancer Res. 51:4845–4852.
1991.PubMed/NCBI
|
|
13
|
Inuyama Y, Kataura A, Togawa K, Saijo S,
Satake B, Takeoda S, Konno A, Ebihara S, Sasaki Y, Kida A, et al:
Late phase II clinical study of RP56976 (docetaxel) in patients
with advanced/recurrent head and neck cancer. Gan To Kagaku Ryoho.
26:107–116. 1999.(In Japanese). PubMed/NCBI
|
|
14
|
Ueyama Y, Okafuji M, Harada K, Mano T,
Mihara M, Uchida K, Horinaga D and Wada N: Clinical phase I trial
of S-1 in the combination with DOC using super-selective
intra-arterial infusion with oral cancer. Gan To Kagaku Ryoho.
36:395–399. 2009.(In Japanese). PubMed/NCBI
|
|
15
|
Wierstra I and Alves J: FOXM1, a typical
proliferation-associated transcription factor. Biol Chem.
388:1257–1274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tuteja G and Kaestner KH: SnapShot:
Forkhead transcription factors I. Cell. 130:11602007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tuteja G and Kaestner KH: Forkhead
transcription factors II. Cell. 131:1922007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu M, Dai B, Kang SH, Ban K, Huang FJ,
Lang FF, Aldape KD, Xie TX, Pelloski CE, Xie K, et al: FoxM1B is
overexpressed in human glioblastomas and critically regulates the
tumorigenicity of glioma cells. Cancer Res. 66:3593–3602. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yau C, Wang Y, Zhang Y, Foekens JA and
Benz CC: Young age, increased tumor proliferation and FOXM1
expression predict early metastatic relapse only for
endocrine-dependent breast cancers. Breast Cancer Res Treat.
126:803–810. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Okada K, Fujiwara Y, Takahashi T, Nakamura
Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori
M and Doki Y: Overexpression of forkhead box M1 transcription
factor (FOXM1) is a potential prognostic marker and enhances
chemoresistance for docetaxel in gastric cancer. Ann Surg Oncol.
20:1035–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu N, Zhang X, Wang X, Ge HY, Wang XY,
Garfield D, Yang P, Song YL and Bai CX: FoxM1 mediated resistance
to gefitinib in non-small-cell lung cancer cells. Acta Pharmacol
Sin. 33:675–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Carr JR, Park HJ, Wang Z, Kiefer MM and
Raychaudhuri P: FoxM1 mediates resistance to herceptin and
paclitaxel. Cancer Res. 70:5054–5063. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li X, Yao R, Yue L, Qiu W, Qi W, Liu S,
Yao Y and Liang J: FOXM1 mediates resistance to docetaxel in
gastric cancer via up-regulating Stathmin. J Cell Mol Med.
18:811–823. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li X, Qiu W, Liu B, Yao R, Liu S, Yao Y
and Liang J: Forkhead box transcription factor 1 expression in
gastric cancer: FOXM1 is a poor prognostic factor and mediates
resistance to docetaxel. J Transl Med. 11:2042013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lok GT, Chan DW, Liu VW, Hui WW, Leung TH,
Yao KM and Ngan HY: Aberrant activation of ERK/FOXM1 signaling
cascade triggers the cell migration/invasion in ovarian cancer
cells. PLoS One. 6:e237902011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Laoukili J, Stahl M and Medema RH: FoxM1:
At the crossroads of ageing and cancer. Biochim Biophys Acta.
1775:92–102. 2007.PubMed/NCBI
|
|
27
|
Wang Z, Banerjee S, Kong D, Li Y and
Sarkar FH: Down-regulation of Forkhead Box M1 transcription factor
leads to the inhibition of invasion and angiogenesis of pancreatic
cancer cells. Cancer Res. 67:8293–8300. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kalinichenko VV, Major ML, Wang X,
Petrovic V, Kuechle J, Yoder HM, Dennewitz MB, Shin B, Datta A,
Raychaudhuri P and Costa RH: Foxm1b transcription factor is
essential for development of hepatocellular carcinomas and is
negatively regulated by the p19ARF tumor suppressor. Genes Dev.
18:830–850. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bektas N, Haaf At, Veeck J, Wild PJ,
Lüscher-Firzlaff J, Hartmann A, Knüchel R and Dahl E: Tight
correlation between expression of the Forkhead transcription factor
FOXM1 and HER2 in human breast cancer. BMC Cancer. 8:422008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gialmanidis IP, Bravou V, Amanetopoulou
SG, Varakis J, Kourea H and Papadaki H: Overexpression of hedgehog
pathway molecules and FOXM1 in non-small cell lung carcinomas. Lung
Cancer. 66:64–74. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kalin TV, Wang IC, Ackerson TJ, Major ML,
Detrisac CJ, Kalinichenko VV, Lyubimov A and Costa RH: Increased
levels of the FoxM1 transcription factor accelerate development and
progression of prostate carcinomas in both TRAMP and LADY
transgenic mice. Cancer Res. 66:1712–1720. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chan DW, Yu SY, Chiu PM, Yao KM, Liu VW,
Cheung AN and Ngan HY: Over-expression of FOXM1 transcription
factor is associated with cervical cancer progression and
pathogenesis. J Pathol. 215:245–252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li Q, Zhang N, Jia Z, Le X, Dai B, Wei D,
Huang S, Tan D and Xie K: Critical role and regulation of
transcription factor FoxM1 in human gastric cancer angiogenesis and
progression. Cancer Res. 69:3501–3509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang X, Wu E, Wu J, Wang TL, Hsieh HP and
Liu X: An antimitotic and antivascular agent BPR0L075 overcomes
multidrug resistance and induces mitotic catastrophe in
paclitaxel-resistant ovarian cancer cells. PLoS One. 8:e656862013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhao F, Siu MK, Jiang L, Tam KF, Ngan HY,
Le XF, Wong OG, Wong ES, Gomes AR, Bella L, et al: Overexpression
of forkhead box protein M1 (FOXM1) in ovarian cancer correlates
with poor patient survival and contributes to paclitaxel
resistance. PLoS One. 9:e1134782014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Khongkow P, Gomes AR, Gong C, Man EP,
Tsang JW, Zhao F, Monteiro LJ, Coombes RC, Medema RH, Khoo US and
Lam EW: Paclitaxel targets FOXM1 to regulate KIF20A in mitotic
catastrophe and breast cancer paclitaxel resistance. Oncogene.
35:990–1002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
de Moraes Nestal G, Delbue D, Silva KL,
Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL,
Magalhães LM, et al: FOXM1 targets XIAP and Survivin to modulate
breast cancer survival and chemoresistance. Cell Signal.
27:2496–2505. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Khongkow P, Karunarathna U, Khongkow M,
Gong C, Gomes AR, Yagüe E, Monteiro LJ, Kongsema M, Zona S, Man EP,
et al: FOXM1 targets NBS1 to regulate DNA damage-induced senescence
and epirubicin resistance. Oncogene. 33:4144–4155. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Radhakrishnan SK, Bhat UG, Hughes DE, Wang
IC, Costa RH and Gartel AL: Identification of a chemical inhibitor
of the oncogenic transcription factor forkhead box M1. Cancer Res.
66:9731–9735. 2006. View Article : Google Scholar : PubMed/NCBI
|
